Aggressive Gliomatosis Peritonei Arising from Ovarian Mature Teratoma with NF1 Mutation: A Case Report and Literature Review

Chang Liu; Bin Yan; You Wang; Wen Di; Weihua Lou

doi:10.2147/CMAR.S374987

Aggressive Gliomatosis Peritonei Arising from Ovarian Mature Teratoma with NF1 Mutation: A Case Report and Literature Review

Cancer Manag Res. 2022 Oct 12:14:2979-2986. doi: 10.2147/CMAR.S374987. eCollection 2022.

Authors

Chang Liu^#^{1

2}, Bin Yan^#^{1

2}, You Wang^#^{1

2}, Wen Di^{1

2}, Weihua Lou^{1

2}

Affiliations

¹ Department of Obstetrics and Gynecology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
² Shanghai Key Laboratory of Gynecologic Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.

^# Contributed equally.

Abstract

Background: GP arising from ovarian mature teratoma is a rare disease, and no confirmed pathogenesis signature genes are reported. The progress of GP is seen as relatively slow. Rare aggressive GP cases with poor prognosis were reported and no guidelines to follow for treatment.

Case presentation: Herein, we report a 17-year-old girl with a 3-year-history of GP arising from ovarian mature teratoma. Surgeries and drug therapy were used to treat the aggressively growing tumour. Genetic profiling revealed the pathogenic mutation with potential therapeutic approaches. We firstly reported the NF1 mutations in GP secondary to teratomas and may cause bad prognosis.

Conclusion: GP arising from ovarian mature teratoma is rare; we found NF1 mutation could be the trigger of GP. The study may provide new insights into a better understanding of this rare disease.

Keywords: MGMT promoter methylation; NF1 mutation; Trametinib; genetic profile; gliomatosis peritonei; ovarian mature teratoma.

Publication types

Case Reports

Grants and funding

This project was funded by National Natural Science Foundation of China, grant number 82172918, the Shanghai Municipal Commission of Health, grant number 201940284, the Medical-Engineering Joint Funds of Shanghai Jiao Tong University, grant number YG2021GD01. The cost of the publication was supported by the funding. The funding bodies played no role in the design of the study, data collection, analysis, and interpretation, decision to publish, or writing the manuscript.